A Study of SHR-1802 in Patients With Advanced Solid Tumor

NCT05208177 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Adjustment of R\&D strategy

Conditions

Advanced Solid Tumor

Interventions

DRUG: SHR-1802＋camrelizumab + famitinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.